-+ 0.00%
-+ 0.00%
-+ 0.00%

Toyobo Records ¥6.5 Billion Impairment Loss in Pharmaceutical Contract Manufacturing

PUBT·11/09/2026 04:07:01
Listen to the news
Toyobo Records ¥6.5 Billion Impairment Loss in Pharmaceutical Contract Manufacturing
  • Toyobo recorded JPY 6.5 billion in extraordinary impairment losses in its pharmaceutical contract manufacturing business in the quarter ended September 30, 2026.
  • Competing products reduced orders, prompting a business-plan revision that lowered asset recoverable values below book values.
  • Full-year net profit forecast for the year ending March 31, 2027, cut 42.9% to JPY 4 billion from JPY 7 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Toyobo Co. Ltd. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.